Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02472977 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 1
- Development phase
- 61
- Enrollment target
NCT02472977 is a Phase 1 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 61 participants.
The verdict
NCT02472977, a Phase 1 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 61 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the combination of Ulocuplumab and Nivolumab is safe and effective in the treatment of pancreatic cancer and small cell lung cancer.
Interventions
- DRUG Nivolumab
- DRUG Ulocuplumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2015-07-13 |
| Est. Completion | 2017-01-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02472977
The ClinicalTrials.gov registry entry for NCT02472977 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT02472977 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02472977 about?
NCT02472977 is a clinical study titled "Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors". The purpose of this study is to determine whether the combination of Ulocuplumab and Nivolumab is safe and effective in the treatment of pancreatic cancer and small cell lung cancer.
What is the current status of trial NCT02472977?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 61 participants. The study started on 2015-07-13. Estimated completion is 2017-01-27.
What interventions are being tested in trial NCT02472977?
The interventions under investigation include: Nivolumab (DRUG), Ulocuplumab (DRUG).
Who is sponsoring clinical trial NCT02472977?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.